Neurologic complications and considerations in HIV-infected persons

Current Infectious Disease Reports

Volumn 15, Issue 1, 2013, Pages 61-66

  McArthur, Justin ^a   Smith, Bryan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CNS; HAND; HIV; HIV sensory neuropathy; HIV associated neurocognitive disorder; neuroHIV; Neurologic; Review

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; DIDANOSINE; DULOXETINE; GABAPENTIN; GLYCOPROTEIN GP 120; MEMANTINE; MINOCYCLINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PREGABALIN; SELEGILINE; STAVUDINE; TRANSACTIVATOR PROTEIN; VIRUS RNA; ZALCITABINE;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANTIVIRAL THERAPY; APTITUDE TEST; BLOOD BRAIN BARRIER; BRAIN REGION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL INVASION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; COGNITIVE REHABILITATION; CYTOKINE RELEASE; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EXPOSURE; HIV ASSOCIATED DEMENTIA; HIV ASSOCIATED SENSORY NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; MACROPHAGE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MONOCYTE; MOOD DISORDER; NERVE CELL LESION; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; PATHOGEN LOAD; PATHOGENESIS; PATIENT CARE; POLYNEUROPATHY; POPULATION RESEARCH; PROTEIN FUNCTION; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RNA ANALYSIS; SENSORY NEUROPATHY; SUBSTANCE ABUSE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84873096391     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0312-2     Document Type: Review

References (50)

1. Peluso R, Haase A, Stowring L, et al. A Trojan horse mechanism for the spread of visna virus in monocytes. Virology. 1985;14:231-6.
2. Yoshioka M, Bradley M, Shapshak P, et al. Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Adv Neuroimmunol. 1995;5:335-58.
3. Gonzalez-Scarano F, Martin-Garcia J. The Neuropathogensis of AIDS. Nat Rev Immunol. 2005;19:69-81.
4. Martin A. HIV, cognition, and the basal ganglia. In: Grant I, Martin A, editors. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994. p. 234-59.
5. Ances BM, Ortega M, Vaida F, et al. Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 2012;59:469-77.
6. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population based study. Neurology. 2010;75:1150-8.
7. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275-82.
8. Peterson J, Lee E, Hecht F, et al.: Changes in neurocognitive performance from early HIV-1 infection to initiation of ART [Abstract 80]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5-8, 2012.
9. Lee E, Gisslen M, Cinque P, et al.: Early follow up of undetectable cerebrospinal fluid HIV-1 RNA during primary infection in the absence of ART [Abstract 457]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5-8, 2012.
10. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-99. These consensus guidelines for diagnosing forms of HAND not only are important for researchers, but also are valuable for clinicians, especially with the understanding of how the different forms vary by level of testing performance and level of daily impairments. Additionally, the article includes descriptions of how cognitive impairments in HIV-infected persons have changed over the years, and it is important to clinically recognize the often subtler symptoms that are prevalent now.
11. Heaton RK, Clifford DB, Franklin DR JR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087-96. This large multicenter cohort study with strong methodology highlights the overwhelming prevalence of HAND in the HIV population.
12. Gorman AA, Foley JM, Ettenhofer ML, et al. Functional consequences of HIV-associated neurocognitive impairment. Neuropsychol Rev. 2009;19:186-203. This extensive and well-organized review of outcomes for patients affected with HAND emphasizes the role that even subtle disease can have major impacts on activities of daily living.
13. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:273-8.
14. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367-74.
15. Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10:246-52.
16. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75:864-73.
17. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357-65.
18. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1and cognition after starting potent antiretroviral therapy. Neurology. 2003;60:1388-90.
19. Moore DJ, Roediger M, Eberly L. Clinical Evaluation of Neurocognitive and Neuropsychiatric Dysfunction [Abstract 499]. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; March 5-8, 2012.
20. Koski L, Brouillette MJ, Lalonde R, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment. HIV Med. 2011;12:472-80.
21. Cysique LA, Murray JM, Dunbar M, et al. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med. 2010;11:642-9. This study describes a quick bedside questionnaire for screening patients for HAND with good sensitivity and specificity.
22. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-51.
23. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-73.
24. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45:174-82.
25. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69:2213-20.
26. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77:1135-42.
27. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11:59-67.
28. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials. 2007;8:437-46.
29. Iudicello JE, Kellogg EJ, Weber E, et al. Semantic cueing improves category verbal fluency in persons living with HIV infection. J Neuropsychiatry Clin Neurosci. 2012;24:183-90.
30. Weber E, Woods SP, Kellogg E, Grant I, Basso MR. Self-generation enhances verbal recall in individuals infected with HIV. J Int Neuropsychol Soc. 2012;18:128-33.
31. Cusini A, Vernazza PL, Yerly S, et al.: Higher CNS Penetration- Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28-35.
32. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-66.
33. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292-9.
34. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78:485-92.
35. Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4:190-9.
36. Green DA, Masliah E, Vinters HV, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19:407-11.
37. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127-35. The authors report on how the HIV-1 protein inhibits amyloid clearance but also describe how this inhibition actually leads to CNS amyloid deposition. The discussion concisely summarizes the clinical implications of amyloid deposition in HIV-infected patients.
38. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998;65:29-33.
39. Ellis RJ, Rosario D, Clifford DB, et al. ontinued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552-8. The authors report on HIV-SN within a large cohort of HIV-positive patients and describe very high prevalence despite the use of CART and the numerous risk factors that are associated with HIV-SN.
40. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607-13.
41. Tagliati M, Grinnell J, Godbold J, et al. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56:84-9.
42. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol. 2004;61:546-51.
43. Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology. 2002;58:1764-8.
44. Fellows RP, Byrd DA, Elliott K, et al. Distal sensory polyneuropathy is associated with neuropsychological test performance among persons with HIV. J Int Neuropsychol Soc. 2012;18:898-907.
45. Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology. 2007;68:2113-9.
46. Keswani SC, Jack C, Zhou C, et al. Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci. 2006;26:10299-304.
47. Wallace VC, Blackbeard J, Segerdahl AR, et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain. 2007;130:2688-702.
48. Brittain JM, Duarte DB, Wilson SM, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med. 2011;17:822-9.
49. Ripsch MS, Ballard CJ, Khanna M, et al. A peptide uncoupling CRMP-2 from the presynaptic CA(2+) channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl Neurosci. 2012;3:1-8.
50. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433. The meta-analysis section of this paper describes the few published clinical trials of medications that are commonly prescribed for HIV-associated painful neuropathies.